Tsz-Lun Yeung

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

20h-index3.2kcitations107works0.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Cells and Metastasis(23), Cell Adhesion Molecules Research(23), Fibroblast Growth Factor Research(23), Kruppel-like factors research(23), Ovarian cancer diagnosis and treatment(22)

Publications107 total

Abstract 2921: Extended treatment with IAP inhibitor xevinapant post radiotherapy improves therapeutic efficacy and promotes antitumor immunity in preclinical models
Cancer Research·2024· 1 cited
Abstract A094: CAF-derived MFAP5 enhances immune escape through up-regulating immune checkpoint mediator CD47 in ovarian cancer cells and CD8+ T cells
Cancer Research·2024
Supplementary Table 3 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
2023Open Access
Data from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
2023Open Access
Data from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
2023Open Access
Supplementary Figure 4 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
2023Open Access
Data from Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer
2023Open Access
Supplementary Table 1 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
2023Open Access
Supplementary Figure Legend from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
2023Open Access
Supplementary Table 2 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
2023Open Access
Supplementary Figure 4 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
2023Open Access
Supplementary Figure 3 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
2023Open Access
Supplementary Table 2 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
2023Open Access
Supplementary Table 1 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
2023Open Access
Supplementary Figure Legend from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
2023Open Access
Data from Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer
2023Open Access
Supplementary Figure 2 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
2023Open Access
Supplementary Figure 2 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
2023Open Access
Supplementary Data from Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer
2023Open Access
Supplementary Data from Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Samuel C. Mok(45), Cecilia S. Leung(24), Kwong‐Kwok Wong(22), Michael J. Birrer(20), Suet‐Ying Kwan(15), Melissa S. Thompson(14), Tarrik M. Zaid(13), Stephen T.C. Wong(12), Karen H. Lu(11), Gabriel Lopez‐Berestein(11), Anil K. Sood(11), Kay‐Pong Yip(9), Jianting Sheng(9), Rosie S. Schmandt(8), Cristian Rodriguez-Aguay(8), Sammy Ferri‐Borgogno(8), Tom Harding(7), Ngai-Na Co(7), Chi Lam Au Yeung(6), Rosemarie Schmandt(5)